Mission
Sinaptica Therapeutics™ and its co-founders are committed to bringing a safe, effective, and non-invasive electromagnetic therapeutic treatment to Alzheimer’s patients that can help to significantly slow the progression of both cognitive and functional decline. Given the massive toll Alzheimer’s takes on patients, their families and caregivers, our team is working hard toward executing on a pivotal clinical study designed to support our regulatory submission to obtain FDA approval before we can commercialize our Sinaptistim™ AD – System to treat patients in need of safe, proven and effective therapeutic treatments.
About Us
About Alzheimer’s Disease
Alzheimer’s disease is a brain disorder that slowly destroys memory and thinking skills and, eventually, the ability to carry out the simplest tasks. People with Alzheimer’s also experience changes in behavior and personality. According to the Alzheimer’s Association, more than 6 million Americans, many of them age 65 and older, are estimated to have Alzheimer’s disease in 2022. That’s more individuals living with Alzheimer’s disease than the population of a large American city. Many more people experience Alzheimer's in their lives as family members and friends of those with the disease.
The hallmarks of Alzheimer’s disease — changes in thinking, remembering, reasoning, and behavior - progress during a few years and lead to dementia. That’s why Alzheimer’s is sometimes referred to as “dementia.” Other diseases and conditions can also cause dementia, with Alzheimer’s being the most common cause of dementia in older adults. Alzheimer’s disease is not a normal part of aging. It’s the result of complex changes in the brain that start some 20 years before symptoms appear and lead to the loss of brain cells and their connections. Currently, there are no approved or available disease modifying treatments that have been proven to be clinically effective in slowing the progression of cognitive and functional decline associated with Alzheimer’s disease.
